Eliava Institute
The George Eliava Institute, founded in 1923 in Tbilisi, Georgia, is a state-owned research institute operating one of the world's largest bacteriophage collections (1,000+ phages, 12,000+ strains). It delivers integrated phage therapy, diagnostics, commercial phage preparations, and accredited international training programs.
- Company typePrivate
- Founded1923
- HeadquartersT'elavi, Georgia
- Headcount101–250
- GTM typeB2B and B2C
- OfferingServices
What Eliava Institute does
The George Eliava Institute of Bacteriophages, Microbiology and Virology is a Georgian state-owned research institute founded in 1923 in Tbilisi by George Eliava and Felix d'Herelle, the co-discoverer of bacteriophages. Its core asset is one of the world's largest phage collections — more than 1,000 bacteriophage preparations and 12,000+ bacterial strains spanning 44 genera — built continuously over a century. The institute operates a 'one window' service model that integrates diagnostic testing, personalized phage formulation, and clinical treatment in a single facility, delivered through the Eliava Consortium of five affiliated entities: the institute itself, BioPreparations (industrial production), the Phage Therapy Center (clinical treatment), the Diagnostic Center (ISO 9001:2015 certified laboratory), and the Authorized Pharmacy.
The institute monetizes across four revenue streams: (1) sales of six commercial phage preparations (Pyophage, Intesti, Fersis, Ses, Enko, Staphylococcal bacteriophages) through the Authorized Pharmacy and nationwide chains Pharmadepo and Gepsi; (2) clinical phage therapy for both Georgian and international patients, served via in-person consultations and a telemedicine/specimen-shipping workflow facilitated by medical-tourism partner Caucasus Healing; (3) ISO-certified diagnostic services including pathogen identification and phage susceptibility testing; and (4) educational programs anchored by the EACCME-accredited ESCMID postgraduate course and the annual International Eliava Summer School. Customer segments span individual patients with antibiotic-resistant infections (cystic fibrosis, chronic UTIs, surgical wounds), medical professionals seeking phage therapy training, domestic retail pharmacy buyers, and referring healthcare institutions.
Geographically, the institute serves Georgia as its core market and attracts international patients from France, the USA, Belgium, China, Japan, and elsewhere. It is currently expanding its European institutional footprint via the Horizon Europe ASCLEPIUS Twinning coordinator role, WHO EURO engagement, and partnerships with INRAE, TU Delft, Walter Reed, the US CDC, and the French/German diplomatic missions. Headcount is approximately 101-250, with about 60 researchers and up to 20 physicians at the Phage Therapy Center. Revenue is not publicly disclosed.
Eliava Institute firmographics
Firmographics- Name
- Eliava Institute
- Legal name
- George Eliava Institute of Bacteriophages, Microbiology and Virology
- Website
- https://eliava-institute.org
- Company type
- Private
- Founded year
- 1923
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- The George Eliava Institute, founded in 1923 in Tbilisi, Georgia, is a state-owned research institute operating one of the world's largest bacteriophage collections (1,000+ phages, 12,000+ strains). It delivers integrated phage therapy, diagnostics, commercial phage preparations, and accredited international training programs.
- Ownership category
- akta.pro rank
Eliava Institute industry classification
Industry- Product category
- Bacteriophage Therapy and Research Services
- NAICS
- Medical Laboratories (621511), Pharmaceutical Preparation Manufacturing (325412), Medical and Diagnostic Laboratories (62151)
- SIC
- Services-Medical Laboratories (8071), Pharmaceutical Preparations (2834), Services-Offices & Clinics Of Doctors Of Medicine (8011)
- akta.pro primary industry
- Microbiology & Infectious Disease Diagnostics (Culture/ID/AST) (HLAHAAAC)
- akta.pro secondary industries
- Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG), Microbiology & Infectious Disease Testing Laboratories (HLAFAMAD), General Infectious Disease (HLAKAGAA)
Keywords
Where Eliava Institute is headquartered
LocationHeadquarters
- HQ city
- T'elavi
- HQ country
- Georgia
- HQ region
- Asia
Offices2 records
Markets served
Eliava Institute business model
Business model- GTM type
- B2B and B2C
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Supply Chain
Revenue model
- Phage Preparation Sales: Six commercial phage preparations (Pyophage, Intesti, Fersis, Ses, Enko, and Staphylococcal bacteriophages) sold through the Eliaava Authorized Pharmacy and pharmacy chains Pharmadepo and Gepsi across Georgia.
- Diagnostic Services: Bacteriological, virological, immunological, serological, biochemical, molecular, and general clinical testing provided at the Eliava Diagnostic Center. ISO 9001:2015 certified.
- Phage Therapy Treatment: Clinical phage therapy services at the Eliava Phage Therapy Center, including physician consultations, personalized treatment protocols, and ongoing patient monitoring for both Georgian and international patients.
- Educational Programs: International training courses and summer schools in phage therapy for medical professionals and researchers. The ESCMID-accredited postgraduate course (May 2026) brought together 47 participants from 26 countries.
Go-to-market motion3 records
Distribution channels4 records
Marketing channels7 records
Eliava Institute product offering
Product offeringCore offering
The George Eliava Institute of Bacteriophages, Microbiology and Virology is a state research institute conducting bacteriophage research, isolation, and preparation, and providing clinical phage therapy, diagnostic laboratory services, and pharmaceutical bacteriophage products. Through the Eliava Consortium, it operates a 'one window' model integrating diagnostics, personalized phage preparation, clinical treatment, and pharmacy dispensing under one roof, serving both Georgian and international patients with antibiotic-resistant infections.
Product overview
The Eliava Institute operates as a research institution within the Eliava Consortium, which provides a one-window principle integrating diagnostic, therapeutic, and pharmaceutical services. The consortium's product portfolio includes six serial bacteriophage preparations (Pyobacteriophage/Intesti/Staphylococcal/Ses/Enko/Fersis bacteriophages) produced by the Eliava Biopreparations company, available through the Eliava Authorized Pharmacy. The Eliava Diagnostic Center provides laboratory testing and phage susceptibility analysis, feeding into the Eliava Phage Therapy Center, which delivers clinical phage treatment with individualized personalized phage formulations. The institute's foundational asset is its national bacteriophage and bacterial strain collection of over 1000 phages and 12,000 bacterial strains spanning 44 genera.
Differentiator
Problem solved
Functional benefit
Brands
- Eliava Consortium: Network of related organizations including the Institute, Foundation, BioPreparations, Phage Therapy Center, Diagnostic Center, and Pharmacy operating under shared mission
Products and services
- Pyobacteriophage (Pio)
Quantifiable outcome
- Effective against MRSA, ESBL-producing bacteria, CRE, VRE — pathogens classified as global public health crises by WHO
- +2 more outcomes
Companies that use Eliava Institute
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles4 records
Eliava Institute technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Eliava Institute partnerships and signals
Strategic signalPartnerships
20 partnerships are on record, tiered minor and core.
- INRAE (Institut national de recherche pour l'agriculture, l'alimentation et l'environnement), FranceminorDr. Marie-Agnès Petit and Dr. Quentin Nougier from INRAE France led a specialized workshop on protein function prediction and phage genome annotation using Pharokka, Phold, and Galaxy platforms at the 4th International Eliava Summer School.
- Tbilisi State Medical UniversitycoreJoint organizers of the ESCMID-accredited postgraduate course 'Bacteriophage Therapy and Phage-derived Proteins: Dual Strategies Against Antimicrobial Resistance and for Diagnostic Innovation' (May 10-13, 2026). The institute hosted theoretical and practical seminars while the university provided venue and accreditation. Rector Professor Irakli Natroshvili opened the course.
- WHO EURO and Global AMR R&D HubminorThe institute participated in an international event organized by WHO EURO and the Global Antimicrobial Resistance Research and Development Hub, positioning Georgian phage expertise within global AMR policy frameworks.
- British Scientific DelegationminorA British scientific delegation visited the institute, indicating bilateral research interest and potential scientific collaboration in phage research.
- Walter Reed Army Institute of Research (WRAIR)minorA delegation from the Walter Reed Army Institute of Research visited the institute, reflecting interest in phage applications for military medicine and wound care.
- European Commission — Horizon Europe Twinning Project ASCLEPIUScoreThe institute coordinates the ASCLEPIUS project, a Horizon Europe Twinning initiative that aims to enhance research excellence through partnership with leading European institutions in phage therapy and AMR.
- Eliava Phage Therapy CentercoreClinical treatment facility established in 2010 jointly by the G. Eliava Institute and David Tvildiani Medical University. Provides phage therapy services with up to 20 physicians, serving both Georgian and international patients.
- ESCMID (European Society of Clinical Microbiology and Infectious Diseases)coreESCMID supported the May 2026 postgraduate phage therapy course and provides international accreditation (EACCME) for the institute's educational programs, lending scientific credibility and international visibility.
- Delft University of Technology (TU Delft), NetherlandsminorYoung researcher Elisabed Zaldastanishvili was selected for a three-month research visit to the Faculty of Applied Sciences at Delft University of Technology, representing staff exchange and research collaboration.
- French Parliament's Science Office (Office Parlementaire Scientifique)minorThe Deputy Chair of the French Parliament's Science Office visited the institute, indicating high-level governmental interest in phage science and potential policy collaboration.
- Ambassador of France to GeorgiaminorFrench Ambassador Sheraz Gasri visited the institute, demonstrating diplomatic support for Franco-Georgian scientific cooperation in phage research.
- Ambassador of Germany to Georgia (Ernst Peter Fischer)minorThe German Ambassador visited the institute, reflecting growing European interest in phage science and potential bilateral collaboration.
- US Centers for Disease Control and Prevention (US CDC)minorA high-level CDC delegation visited the institute, indicating US government health agency interest in alternative antimicrobial strategies.
- Ministry of Health of GeorgiacoreThe Georgian Minister of Health visited the institute, reflecting governmental recognition and support for the institute's role in addressing antimicrobial resistance.
- Tbilisi City Council Healthcare CommissionminorThe Chair and members of the Tbilisi City Council Commission on Healthcare and Social Issues visited the institute and Phage Therapy Center, underscoring local governmental recognition of the institute's national importance.
- EU Horizon 2020 — Phage Research ConsortiumcoreEU-funded project studying phages' role in asthma, involving scientists from 6 countries. Nino Chanisvili manages the Georgian side of this multi-national phage research initiative.
- Eliava BioPreparations (phage.ge)corePart of the Eliava Consortium, this company handles industrial-scale production of phage preparations based on the institute's research.
- Eliava Diagnostic Center (bacteriophage.ge)coreDiagnostic laboratory within the Eliava Consortium providing bacteriological, virological, immunological, serological, and molecular testing services. ISO 9001:2015 certified.
- Eliava FoundationcoreNon-profit 'Association for Development of Bacteriophages in Georgia' established by institute scientists. Its goal is sustainable development of the institute and popularization of bacteriophages. Parent organization of the Eliava Consortium.
- Caucasus Healing Medical Tourism AgencyminorMedical tourism agency founded by French-Georgian couple Alain Lavit and Irma Jejeia, facilitating international patients (primarily French) seeking phage therapy at the institute since 2016.
Scale indicators5 records
Recent moves7 records
Expansion highlights6 records
Eliava Institute competitors and assessment
Company assessmentDirect peers
- Adaptive Phage Therapeutics: US-based clinical-stage phage therapy company developing personalized phage treatments for antibiotic-resistant infections; directly comparable to Eliava's personalized phage preparation model and patient-driven approach.
- Armata Pharmaceuticals: US clinical-stage biotech developing phage-based therapeutics for antibiotic-resistant infections including Pseudomonas aeruginosa in cystic fibrosis patients; closely comparable in therapeutic focus and AMR positioning.
- TechnoPhage: Portuguese phage biotech developing phage-based products for bacterial infections; closely comparable as a European-based clinical phage research company with academic and commercial integration.
- Locus Biosciences: US clinical-stage biotech developing engineered phage products (crPhage platform) for antibiotic-resistant infections including UTIs; comparable in clinical-stage phage therapeutic development targeting the same AMR pathogens.
- Pherecydes Pharma: French phage therapy company developing anti-Staphylococcus aureus and anti-Pseudomonas aeruginosa phage products; directly comparable to Eliava's personalized phage cocktails and AMR focus, with overlapping French patient base.
- Intralytix: US phage-based product company with the FDA-cleared food safety phage products (ListShield, EcoShield) and clinical pipeline targeting human bacterial infections; comparable in phage library approach and commercial production.
Emerging players
- ContraFect Corporation: US biotech developing lysins and other phage-derived enzymes for antibiotic-resistant bacterial infections; comparable in the broader phage-derived antimicrobial space targeting the same pathogens Eliava addresses.
- Fixed Phage: UK-based phage technology company developing immobilized phages for various applications; partially comparable in phage technology platform approach, though more focused on industrial/animal health than human therapeutics.
- Eligo Bioscience: French biotech developing phage-derived precision antimicrobials (eligobiotics) for microbiome engineering and AMR; comparable as European AMR-focused phage platform, but with a synthetic biology approach rather than natural phages.
Regional players
- BioComo: Japanese biotech producing phage-based therapeutics and diagnostics with a long history similar to Eliava; comparable as an established regional phage player, particularly relevant given Eliava's BioJapan exhibition participation.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks1 record
Key highlights6 records
Customer concentration
Eliava Institute social profiles
Digital presenceEliava Institute compliance and trust
Trust signalCompliance1 record
Eliava Institute financial estimates
Financial estimateRevenue estimate
Valuation estimate
Eliava Institute leadership team
Management profileNumber of profiles
Profiles7 records
Eliava Institute subsidiaries and ownership
Company hierarchySubsidiaries5 records
Eliava Institute funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Eliava Institute M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Eliava Institute
What does Eliava Institute do?
The George Eliava Institute of Bacteriophages, Microbiology and Virology is a state research institute conducting bacteriophage research, isolation, and preparation, and providing clinical phage therapy, diagnostic laboratory services, and pharmaceutical bacteriophage products. Through the Eliava Consortium, it operates a 'one window' model integrating diagnostics, personalized phage preparation, clinical treatment, and pharmacy dispensing under one roof, serving both Georgian and international patients with antibiotic-resistant infections.
Is Eliava Institute a public or private company?
Eliava Institute is a private company. It is classified as state government owned and is currently operating.
When was Eliava Institute founded?
Eliava Institute was founded in 1923. It employs 101 to 250 people.
Where is Eliava Institute based?
Eliava Institute is headquartered in T'elavi, Georgia, in the Asia region.
How does Eliava Institute make money?
Four revenue lines are on record. Phage Preparation Sales are the primary driver. The others are diagnostic Services, phage Therapy Treatment and educational Programs.
Who are Eliava Institute's main competitors?
Direct peers on record are Adaptive Phage Therapeutics, Armata Pharmaceuticals, TechnoPhage, Locus Biosciences, Pherecydes Pharma and Intralytix. Emerging players are ContraFect Corporation, Fixed Phage and Eligo Bioscience. BioComo is listed as a regional player.
Does Eliava Institute have an API?
No public API is recorded for Eliava Institute.
What industry is Eliava Institute in?
Eliava Institute's product category is Bacteriophage Therapy and Research Services. Its primary akta.pro industry code is HLAHAAAC, Microbiology & Infectious Disease Diagnostics (Culture/ID/AST), with a secondary code of HLAIAAAG, Infectious Disease & Antimicrobials Pharmaceuticals. Its NAICS code is 621511 and its SIC code is 8071.